ClinicalTrials.gg
CompletedNCT06613906PHARISUpdated Jul 22, 2025

Prevention With Healsea in Adults Against Respiratory Infection Study

An interventional study of Healsea Children nasal spray in Healthy Subjects (HS), sponsored by Lallemand Pharma AG. Completed at 1 site in Bulgaria. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-22.

Sponsored by Lallemand Pharma AG · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Respiratory Tract Infections with a site in Bulgaria — 2 open to participants now, 2 under way, 2 of them phase 3. Respiratory Tract Infections · Bulgaria.

Enrollment
7th of 12
198 · median 199
Started
2024
with 2 others
No phase
3 of 12
none open now
Registered
11th of 12
by date
Lead sponsor
3 of 12
Lallemand Pharma AG

Among the 12 studies in Respiratory Tract Infections with a site in Bulgaria, this one is the 7th largest by enrollment, is one of 3 that started in 2024, is one of 3 with no phase, and was the 11th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

2 of the 12 studies in Respiratory Tract Infections with a site in Bulgaria are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →

Who these studies take

Of the 73 Respiratory Tract Infections studies recruiting now, 33 (45%) set no upper age limit and 32 (44%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Respiratory Tract Infections with a site in Bulgaria, or all of them as a file.
02

Study summary

Healsea® Children is a class IIa medical device. This is an isotonic seawater-based nasal spray supplemented with a natural Symbiofilm™ extract (0.02%) isolated from marine bacteria. Healsea® Children is indicated in children above 6 years to clean and moisten the nose during colds.

Symbiofilm™, which is not a medicinal product is able to protect the nasal mucosa from viruses entrance by forming a protective barrier on the nasal mucosa.

By targeting the nose as entry points for viruses, we hypothesise that Healsea® Children used regularly during the respiratory virus season may prevent upper respiratory tracts infections such as cold or flu with nasal symptoms not only in children (HEALSPIC study, NCT06582589) but also in adults.

The main objective of this premarket clinical investigation is thus to assess the efficacy of Healsea® Children to prevent upper respiratory tract infections with nasal symptoms in healthy adults during 3 treatment periods of 28 days interspersed by 2 wash-out periods of 10 days when compared to adults not taking Healsea® Children.

198 adults will be randomised in the study, 99 in the Healsea® Children group and 99 in the non-treated group.

The subjects will be asked to report the upper respiratory tract infections with nasal symptoms and complication they may have during the study to the physician in charge of the study conduct.

Two study visits and 3 telephone calls are scheduled. The subjects will also complete an electronic diary to report nasal symptoms and adverse events other than upper respiratory tracts infections.

Read the detailed description

Upper respiratory tract infections (URTIs) and sino-nasal symptoms are very frequent.

Human rhinovirus (more than 100 serotypes) is the most common cause, accounting up to 50% viral rhinitis episodes in children and adults. These episodes can last up to 7-10 days and are usually self-limited. Prevalence of acute rhinosinusitis varies with season (higher in the fall and winter months) and climatic variations and increases with a damp environment and air pollution. The incidence of acute rhinitis/rhinosinusitis is very high, estimated to occur from 2 to 5 times per year in the average adult.

Healsea® Children is a class IIa medical device. This is an isotonic seawater-based nasal spray supplemented with a natural Symbiofilm™ extract (0.02%) isolated from marine bacteria. Healsea® Children is indicated in children above 6 years to clean and moisten the nose during colds and rhinitis. The clinical performance of Healsea® Children is supported by the sea water solution and Symbiofilm™. The exact mechanisms by which nasal irrigation works are not known. However, most of the experts agree that it is primarily a mechanical intervention leading to direct cleaning of the nasal mucosa.

The other component of Healsea® Children, Symbiofilm™ is an exopolymeric composition with emulsifying/surfactant properties which enhance the cleansing and moistening of nasal mucosa. Furthermore, a prophylactic activity of Symbiofilm™ against infection by viruses involved in upper respiratory infections i.e., Adenovirus, Rhinovirus, Flu virus and OC 43 Coronavirus has been demonstrated in vitro on human nasal epithelial cells (HNEpC). The antiviral prophylactic activity of Symbiofilm™ is suggested to rely on its physiochemical properties that, by coating the surface of epithelial cells, hinders the viral entry process, thus explaining the reduced viral adsorption and the subsequent reduced onset of infection.

By targeting the nose as entry points for viruses, we hypothesise that Healsea® Children used regularly during the respiratory virus season may prevent upper respiratory tracts infections with nasal symptoms not only in children (HEALSPIC study, NCT06582589) but also in the adult population.

The aim of this two arms prospective randomized open-labelled pre-market clinical investigation, is to establish clinical benefits and clinical safety of Healsea® Children to prevent upper respiratory tract infections with nasal symptoms in healthy adults during 3 treatment periods of 28 days (one puff in each ostril twice daily) interspersed by 2 wash-out periods of 10 days when compared to adults not taking Healsea® Children.

198 children will be randomised in the study, 99 in the Healsea® Children group and 99 in the non-treated group.

The subjects will be asked to immediately call the investigator in case of nasal symptoms and complication of respiratory infection they may have during the study.

Two study visits (Visit 1, Screening/Randomisation at Day 1 and Visit 2, End of study visit at Day 106 up to Day 116) and 3 telephone calls (telephone call 1 TC1 at Day15 ±3 days, TC2 at Day 55 ±3 days and TC3 at Day 95±3days) are scheduled. The subjects will also complete an electronic diary to report nasal symptoms, device deficiencies, and adverse events other than upper respiratory tracts infections from D2 up to end of study (Day 106 up to Day 116).

The duration of patient\'s participation is up to 116 days.

03

Conditions studied

  • Healthy Subjects (HS)

Keywords

  • saline nasal spray
  • upper respiratory tract infection
  • prevention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects will be enrolled if they meet all the following criteria:

  1. Healthy Male/Female subjects ≥18 years
  2. No respiratory tract infection within 15 days before trial entry and at trial entry
  3. Willingness to participate as evidenced by voluntary written and has received a signed and dated copy of the information consent form
  4. Availability of a smartphone throughout the study and an internet connection.

Exclusion criteria

Exclusion Criteria:

Subjects will not be enrolled if one of the following criteria is present:

  1. Known /allergy to any component of the test device
  2. Subject with , severe asthma, perennial allergy, immunodeficiency or cystic fibrosis
  3. Body temperature ≥ 37.8°C
  4. Medical history or any current disease that is considered by the investigator as a reason for non-inclusion
  5. Severe nasal septum deviation or other condition that could cause nasal obstruction such as the presence of nasal polyps
  6. Antibiotic (systemic or per nasal route) or antivirals (systemic) intake within 2 weeks before screening
  7. Systemic or local (nasal route or inhalation) within 4 weeks before screening
  8. Antihistamines intake for allergy when treatment was started from less than 4 weeks before screening
  9. Vaccination against flu or COVID-19 within 6 months before screening
  10. Chronic decongestant use within 2 weeks before screening
  11. Bacterial lysates, or immunostimulants (food supplements excluded) used for prevention of infection within the 6 months before the screening
  12. Prebiotics, probiotics used for prevention of infection within 6 months before the screening
  13. Pregnant/Lactating female or of without hormonal or intrauterine device or double barrier method.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
198 participants (actual)

Study arms

  • Experimental
    Healsea Children treated group

    Subjects of this arm will be treated with Healsea Children nasal spray during 3 treatment periods of 28 days interspersed by 2 wash-out periods of 10 days

  • No intervention
    Untreated arm

    Subjects of this arm will not receive any treatment for the prevention of respiratory tract infection.

Interventions

  • DeviceHealsea Children nasal spray

    dosage: 1 puff in each nostril twice daily during 3 treatment periods of 28 days interspersed by 2 wash-out periods of 10 days

06

What researchers measure

Primary outcomes

  1. Proportion of subjects without any upper respiratory tract infection (URTI) with nasal symptoms during the study.

    The upper respiratory tracts infections with nasal symptoms (blocked nose, runny nose yellow or green discharge, sneezing ) will be collected for each subject throughout the study. An URTI episode with nasal symptoms is defined as follows: (i) at least 1 of the followings must be present: a blocked nose, runny nose, yellow or green nasal discharge, sneezing; (ii) the symptomatic episode must last for at least 3 days.

    Time frame: From the randomization up to Day 116

Secondary outcomes

  1. Number of Upper Respiratory Tract Infections with nasal symptoms during the study

    Upper Respiratory Tract Infections with nasal symptoms will be reported by the subjects to the investigators during the whole study duration and the total number compared between groups

    Time frame: Time Frame: From the randomization up to Day 116

  2. Number of Upper Respiratory Tract Infections complications

    Complications of Upper respiratory Tract Infections (bronchitis, bronchiolitis, pneumoniae, pharyngo-tonsillitis, laryngitis, acute otitis) will be reported by the subjects during the whole study duration and compared between groups

    Time frame: Time Frame: From the randomization up to Day 116

  3. Number of days of use of concomitant treatments that may affect Upper Respiratory Tract Infections symptoms and associated complications

    The number of days of antipyretics intake, systemic or local mucolytics, decongestants, antitussives, systemic and per nasal route antibiotics, local and systemic corticosteroids, systemic antivirals) will be compared between the 2 arms

    Time frame: From the randomization up to Day 116

  4. Number of school days lost due to Upper Respiratory Tract Infections and complications

    Number of school days lost due to Upper Respiratory Tract Infections and complications will be collected during the whole study duration and compared between groups

    Time frame: From the randomization up to Day 116

  5. Assessment of (serious) adverse events and device deficiences throughout the study

    Time frame: From the randomization up to Day 116

07

Study locations

1 site
  • Diagnostics and Consultation Center Convex EOOD,
    Sofia, 1680, Bulgaria
08

References and documents

Publications

  • Williamson S, Dennison L, Greenwell K, Denison-Day J, Mowbray F, Richards-Hall S, Smith D, Bradbury K, Ainsworth B, Little P, Geraghty AWA, Yardley L. Using nasal sprays to prevent respiratory tract infections: a qualitative study of online consumer reviews and primary care patient interviews. BMJ Open. 2022 Jun 30;12(6):e059661. doi: 10.1136/bmjopen-2021-059661. PubMed 35772824 ↗
  • Slapak I, Skoupa J, Strnad P, Hornik P. Efficacy of isotonic nasal wash (seawater) in the treatment and prevention of rhinitis in children. Arch Otolaryngol Head Neck Surg. 2008 Jan;134(1):67-74. doi: 10.1001/archoto.2007.19. PubMed 18209140 ↗
  • Tano L, Tano K. A daily nasal spray with saline prevents symptoms of rhinitis. Acta Otolaryngol. 2004 Nov;124(9):1059-62. doi: 10.1080/00016480410017657. PubMed 15513550 ↗
  • Jaume F, Valls-Mateus M, Mullol J. Common Cold and Acute Rhinosinusitis: Up-to-Date Management in 2020. Curr Allergy Asthma Rep. 2020 Jun 3;20(7):28. doi: 10.1007/s11882-020-00917-5. PubMed 32495003 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Apr 2025, 4 months.

Of 27 industry-sponsored interventional studies with no phase under Respiratory Tract Infections, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 4 months is below that.

Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Sep 26, 2024
StartActual
Nov 29, 2024
Primary completionActual
Apr 28, 2025
CompletionActual
Apr 28, 2025
Last update
Jul 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06613906
Lead sponsor
Lallemand Pharma AG
Responsible party
Sponsor
First posted
Sep 26, 2024
Start date
Nov 29, 2024
Primary completion
Apr 28, 2025
Completion
Apr 28, 2025
Last update
Jul 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion